Pharming Group (NASDAQ:PHAR) Shares Gap Up to $7.27

Pharming Group (NASDAQ:PHAR) gapped up before the market opened on Monday . The stock had previously closed at $7.27, but opened at $8.00. Pharming Group shares last traded at $8.40, with a volume of 2,031 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Friday, May 31st.

Pharming Group Trading Up 10.0 %

The firm has a market cap of $538.72 million, a P/E ratio of -52.50 and a beta of 0.18. The firm has a 50-day simple moving average of $9.21 and a 200-day simple moving average of $10.76.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Wednesday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.20). The company had revenue of $55.59 million during the quarter, compared to analysts’ expectations of $68.43 million. Pharming Group had a negative net margin of 4.01% and a negative return on equity of 4.61%. Research analysts predict that Pharming Group will post -0.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC acquired a new position in Pharming Group (NASDAQ:PHAR) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 17,710 shares of the company’s stock, valued at approximately $202,000. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.